Clinical trial
A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
NCT02057133 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- March 10, 2014
- Completion date
- December 31, 2026
- Enrollment
- 198 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.